Sep 08, 2022 / 02:25PM GMT
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Great. Thank you very much for this session. My name is Mohit Bansal. I'm 1 of the biopharma analysts here at Wells Fargo. And with us, we have Andy, the CFO of Gilead. Thank you very much, Andy, for joining us.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Thank you for having us. Happy to be here.
Questions and Answers:
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity AnalystThank you very much. And then maybe we can begin this session today. I mean you just dropped some interesting data this morning for Trodelvy. So can you talk a little bit about that? And how do you think about the data at this point?
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Sure. Yes. No, it's exciting data. So just to be clear on what Mohit's referring to. This is the Late-breaking abstract at ESMO on the Trodelvy TROPiCS-02 data
Trustpilot
